On July 28, Bristol-Myers Squibb rose 3.05% in regular trading, trading at $64.56/share, with turnover of $169 million. The stock gained momentum as multiple AI-related catalysts converged with an approaching earnings release.

On the news front, the company recently announced an expansion of its partnership with NVIDIA, deploying a DGX SuperPOD system based on the Vera Rubin architecture to build what it described as the pharmaceutical industry's most powerful AI supercomputer. The system is designed to accelerate novel drug target discovery and clinical development, making Bristol-Myers Squibb the first life sciences company globally to deploy the equipment. The financial terms of the transaction were not disclosed.

The NVIDIA collaboration adds to a growing portfolio of AI partnerships. In May, the company deployed Anthropic's Claude Enterprise across more than 30,000 employees for research, clinical development, and corporate operations. It also partnered with Tempus AI to apply artificial intelligence and data science across five initial clinical trial programs in solid tumor oncology. Additionally, the company is scheduled to report quarterly earnings on July 30 before market open, with consensus EPS expected at $1.59.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)